Literature DB >> 7621846

Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety.

A M Galløe1, N Graudal, H R Christensen, J P Kampmann.   

Abstract

A number of randomised studies indicate that a single high dose of aminoglycoside every 24 h may be more efficient and less toxic than the same dose divided into multiple daily doses. In the meta-analysis of 16 studies described here, which included more than 1200 patients, the relative chance (i.e. the relative risk, RR) of cure of the single-dose regime compared with the multiple-dose regime was 1.027, indicating that the single daily dose regime had a 2.7% higher cure rate (NS). The RR of avoiding nephrotoxicity was 1.001 (NS) and the RR of avoiding ototoxicity was 1.001 (NS). It is concluded that there is no difference concerning efficacy and safety between single-dose and multiple-dose regimes for administration of aminoglycosides.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7621846     DOI: 10.1007/bf00202170

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

Review 1.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity?

Authors:  L Nordström; H Ringberg; S Cronberg; O Tjernström; M Walder
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

3.  Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.

Authors:  E W ter Braak; P J de Vries; K P Bouter; S G van der Vegt; G C Dorrestein; J W Nortier; A van Dijk; R P Verkooyen; H A Verbrugh
Journal:  Am J Med       Date:  1990-07       Impact factor: 4.965

Review 4.  Efficacy and safety of aminoglycosides once-a-day: experimental and clinical data.

Authors:  P M Tulkens
Journal:  Scand J Infect Dis Suppl       Date:  1990

5.  Comparison of once-daily and thrice-daily netilmicin regimens in serious systemic infections: a multicenter study in six Asian countries.

Authors:  E H Mauracher; W Y Lau; H Kartowisastro; K H Ong; V X Genato; B Limson; G M Yusi; C Y Liu; P Suwangool
Journal:  Clin Ther       Date:  1989 Sep-Oct       Impact factor: 3.393

6.  Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections.

Authors:  P J de Vries; R P Verkooyen; P Leguit; H A Verbrugh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-03       Impact factor: 3.267

7.  A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections.

Authors:  L F Hollender; J Bahnini; N De Manzini; W Y Lau; S T Fan; K Hermansyur; P Benny; A N Husni; R R Lorber
Journal:  J Antimicrob Chemother       Date:  1989-05       Impact factor: 5.790

8.  Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections.

Authors:  H Giamarellou; K Yiallouros; G Petrikkos; E Moschovakis; E Vavouraki; D Voutsinas; P Sfikakis
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

9.  Once versus thrice daily gentamicin in patients with serious infections.

Authors:  J M Prins; H R Büller; E J Kuijper; R A Tange; P Speelman
Journal:  Lancet       Date:  1993-02-06       Impact factor: 79.321

10.  Comparative trial of single-dose versus twice-daily sisomicin in bacteriuric patients.

Authors:  J Klastersky; J M Prévost; F Meunier-Carpentier; D Daneau; M Gerard
Journal:  J Clin Pharmacol       Date:  1977 Aug-Sep       Impact factor: 3.126

View more
  12 in total

1.  Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administration.

Authors:  M LeBrun; L Grenier; P Gourde; M G Bergeron; G Labrecque; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 3.  Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?

Authors:  M L Barclay; C M Kirkpatrick; E J Begg
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

4.  Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.

Authors:  C M Kirkpatrick; S B Duffull; E J Begg
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

5.  THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS.

Authors:  Chris Kenyon; Nicci Wearne; Rosie Burton; Graeme Meintjes
Journal:  South Afr J HIV Med       Date:  2011       Impact factor: 2.744

Review 6.  Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis.

Authors:  E Nestaas; H-J Bangstad; L Sandvik; K-O Wathne
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-04-27       Impact factor: 5.747

7.  Aminoglycoside use in renal failure.

Authors:  S Nayak-Rao
Journal:  Indian J Nephrol       Date:  2010-07

Review 8.  Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Authors:  Richard S Slavik; Peter J Jewesson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.

Authors:  Aliasgar Esmail; Natasha F Sabur; Ikechi Okpechi; Keertan Dheda
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

10.  Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up.

Authors:  Prahlad Duggal; Malay Sarkar
Journal:  BMC Ear Nose Throat Disord       Date:  2007-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.